IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotech company specializing in engineered IgM antibodies, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. CEO Fred Schwarzer and Head of Research & Autoimmunity, Dr. Mary Beth Harler, will engage in a fireside chat on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
The event will be accessible via a live webcast on the company's investor relations website. Interested parties can view the presentation through the 'Events and Presentations' page. For those unable to attend live, a replay will be available on the company's website for 90 days following the presentation, ensuring widespread access to this important industry event.
IGM Biosciences (Nasdaq: IGMS), un'azienda biofarmaceutica in fase clinica specializzata in anticorpi IgM ingegnerizzati, ha annunciato la sua partecipazione al Stifel 2024 Virtual Immunology and Inflammation Summit. Il CEO Fred Schwarzer e la Responsabile della Ricerca e Autoimmunità, Dr.ssa Mary Beth Harler, parteciperanno a una conversazione informale il martedì 17 settembre 2024 alle 9:00 EDT.
L'evento sarà accessibile tramite una diretta webcast sul sito web delle relazioni con gli investitori dell'azienda. Le parti interessate possono visualizzare la presentazione attraverso la pagina 'Eventi e Presentazioni'. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione sul sito dell'azienda per 90 giorni dopo la presentazione, garantendo un ampio accesso a questo importante evento del settore.
IGM Biosciences (Nasdaq: IGMS), una empresa biofarmacéutica en etapa clínica especializada en anticuerpos IgM diseñados, ha anunciado su participación en el Stifel 2024 Virtual Immunology and Inflammation Summit. El CEO Fred Schwarzer y la Jefa de Investigación e Autoimmunidad, Dra. Mary Beth Harler, participarán en una charla informal el martes 17 de septiembre de 2024 a las 9:00 a.m. EDT.
El evento será accesible a través de una transmisión en vivo en el sitio web de relaciones con los inversores de la empresa. Las partes interesadas pueden ver la presentación a través de la página 'Eventos y Presentaciones'. Para aquellos que no puedan asistir en vivo, una repetición estará disponible en el sitio web de la empresa durante 90 días después de la presentación, asegurando un acceso amplio a este importante evento de la industria.
IGM 바이오사이언스(Nasdaq: IGMS)는 엔지니어링된 IgM 항체에 전문화된 임상 단계의 생명공학 회사로서 Stifel 2024 Virtual Immunology and Inflammation Summit에 참여한다고 발표하였습니다. CEO인 Fred Schwarzer와 연구 및 자가면역 책임자 Dr. Mary Beth Harler가 2024년 9월 17일 화요일 오전 9:00 EDT에 대화에 참여할 예정입니다.
이 이벤트는 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 접근할 수 있습니다. 관심 있는 분들은 '이벤트 및 발표' 페이지를 통해 발표를 시청할 수 있습니다. 라이브로 참석할 수 없는 분들을 위해 발표 후 90일 동안 회사 웹사이트에서 재생이 가능하여 이 중요한 산업 이벤트에 널리 접근할 수 있도록 보장합니다.
IGM Biosciences (Nasdaq: IGMS), une entreprise biopharmaceutique en phase clinique spécialisée dans les anticorps IgM ingénierie, a annoncé sa participation au Stifel 2024 Virtual Immunology and Inflammation Summit. Le PDG Fred Schwarzer et la Responsable de la Recherche et de l'Auto-immunité, Dr. Mary Beth Harler, participeront à une discussion informelle le mardi 17 septembre 2024 à 9h00 EDT.
L'événement sera accessible via un webinaire en direct sur le site Web des relations investisseurs de l'entreprise. Les personnes intéressées peuvent visionner la présentation via la page 'Événements et Présentations'. Pour ceux qui ne peuvent pas y assister en direct, un replay sera disponible sur le site de l'entreprise pendant 90 jours après la présentation, assurant ainsi un large accès à cet événement important de l'industrie.
IGM Biosciences (Nasdaq: IGMS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf entwickelte IgM-Antikörper spezialisiert hat, hat die Teilnahme am Stifel 2024 Virtual Immunology and Inflammation Summit angekündigt. CEO Fred Schwarzer und die Leiterin der Forschung und Autoimmunität, Dr. Mary Beth Harler, werden am Dienstag, den 17. September 2024 um 9:00 Uhr EDT an einem Gespräch teilnehmen.
Die Veranstaltung wird über einen Live-Webcast auf der Website der Investor Relations des Unternehmens zugänglich sein. Interessierte können die Präsentation über die Seite 'Veranstaltungen und Präsentationen' einsehen. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung 90 Tage lang auf der Website des Unternehmens verfügbar sein, sodass ein breiter Zugang zu diesem wichtigen Branchenevent gewährleistet ist.
- None.
- None.
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
When is IGM Biosciences (IGMS) presenting at the Stifel 2024 Virtual Immunology and Inflammation Summit?
Who will be representing IGM Biosciences (IGMS) at the Stifel 2024 summit?
How can investors access the IGM Biosciences (IGMS) presentation at the Stifel 2024 summit?
How long will the replay of IGM Biosciences' (IGMS) Stifel 2024 summit presentation be available?
